Table 3.

Select ADCC-inducing antibodies undergoing clinical trials.

Target	Antibody	Type	Status, selected active clinical trials
HER2	Trastuzumab	Humanized IgG1	FDA approved: breast cancer and gastric/GEJ cancer
	Margetuximab	Fc modified, chimeric IgG1191	FDA approved: breast cancer Phase II/III: Gastric/GEJ cancer (NCT04082364)
CD20	Rituximab	Chimeric IgG1	FDA approved: NHL and CLL Phase II: ALL (NCT02199184)
	Ofatumumab	Human IgG1	FDA approved: CLL Phase II: NHL, ALL (NCT02199184)
	Obinutuzumab	Afucosylated, Fc modified, humanized IgG1250	FDA approved: CLL and FL Phase II: NHL (NCT03198026), hairy cell leukaemia (NCT03410875)
	Ublituximab	Low fucose, chimeric IgG1250	Phase III: CLL (NCT02612311) Phase II: NHL (NCT02793583)
CD19	Tafasitamab	Fc modified, humanized IgG1251	FDA approved: R/R DLBCL Phase I: NHL (NCT04661007)
EGFR	Cetuximab	Chimeric IgG1	FDA approved: head and neck cancers, colorectal cancer Phase II: NSCLC (NCT04648189)
GD2	Dinutuximab	Chimeric IgG1	FDA approved: neuroblastoma Phase I: High risk and R/R neuroblastoma (NCT02573896)
PD-L1	Avelumab	Human IgG1	FDA approved: Merkel cell carcinoma, urothelial carcinoma and renal cell carcinoma Phase I/II: Gestational trophoblastic neoplasia (NCT04396223), squamous cell anal carcinoma (NCT03944252)
SLAMF7	Elotuzumab	Humanized IgG1	FDA approved: MM Phase II: R/R MM (NCT03361306)
CD38	Daratumumab	Human IgG1	FDA approved: MM Phase III: SMM (NCT03937635) Phase II: R/R MM (NCT03841565)
	Isatuximab	Chimeric IgG1	FDA approved: MM Phase III: SMM (NCT04270409) Phase II: R/R MM (NCT04287855)

Abbreviations: ALL, acute lymphocytic leukaemia; CLL, chronic lymphocytic leukaemia CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma, FL, follicular lymphoma; GEJ, gastroesophageal junction; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; NSCLC, non-small cell lung cancer; R/R, relapsed/refractory; SMM, smoldering multiple myeloma